Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.

Minne H, Audran M, Simões ME, Obermayer-Pietsch B, Sigurðsson G, Marín F, Dalsky GP, Nickelsen T

Current medical research and opinion6 Oct 2008Cited by 25 (Europe PMC)

PMID18838053DOI10.1185/03007990802466595PepBankPUB-18838053

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In inadequate AR responders, lumbar spine BMD increased by 6.2% from baseline during teriparatide treatment.
In plain wordsIn women with inadequate prior treatment responses, spine bone density increased by 6.2% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in inadequate AR responders
Study
n = 421
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Lumbar spine BMD increase
6.2%
inadequate AR responders
95% CI lower
5.6%
inadequate AR responders
95% CI upper
6.9%
inadequate AR responders
Source sentences
Summary
Lumbar spine BMD increased from baseline (p < 0.001) in the three groups (mean, 95% CI); treatment-naïve: 8.4% (7.4%, 9.3%); AR-pretreated: 7.1% (6.3%, 7.9%); inadequate AR-responders: 6.2% (5.6%, 6.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805303
02HumanNon-randomized trialEfficacy outcome
In inadequate AR responders, total hip BMD did not change significantly from baseline during teriparatide treatment.
In plain wordsIn women with inadequate prior treatment responses, hip bone density did not change significantly from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD in inadequate AR responders
Study
n = 421
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Total hip BMD change
−0.3%
inadequate AR responders
95% CI lower
−0.9%
inadequate AR responders
95% CI upper
0.2%
inadequate AR responders
Source sentences
Summary
Total hip BMD increased from baseline in the treatment-naïve (p < 0.001): 1.8% (1.1%, 2.5%) but did not change in the AR-pretreated: 0.4% (-0.2%, 1.1%) or inadequate AR-responders: -0.3% (-0.9%, 0.2%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805306
03HumanNon-randomized trialEfficacy outcome
In AR-pretreated women with osteoporosis, lumbar spine BMD increased by 7.1% from baseline during teriparatide treatment.
In plain wordsIn previously treated women with osteoporosis, spine bone density increased by 7.1% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in AR-pretreated women
Study
n = 240
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Lumbar spine BMD increase
7.1%
AR-pretreated
95% CI lower
6.3%
AR-pretreated
95% CI upper
7.9%
AR-pretreated
Source sentences
Summary
Lumbar spine BMD increased from baseline (p < 0.001) in the three groups (mean, 95% CI); treatment-naïve: 8.4% (7.4%, 9.3%); AR-pretreated: 7.1% (6.3%, 7.9%); inadequate AR-responders: 6.2% (5.6%, 6.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805302
04HumanNon-randomized trialEfficacy outcome
In AR-pretreated women, total hip BMD did not change significantly from baseline during teriparatide treatment.
In plain wordsIn previously treated women, hip bone density did not change significantly from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD in AR-pretreated women
Study
n = 240
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Total hip BMD change
0.4%
AR-pretreated
95% CI lower
−0.2%
AR-pretreated
95% CI upper
1.1%
AR-pretreated
Source sentences
Summary
Total hip BMD increased from baseline in the treatment-naïve (p < 0.001): 1.8% (1.1%, 2.5%) but did not change in the AR-pretreated: 0.4% (-0.2%, 1.1%) or inadequate AR-responders: -0.3% (-0.9%, 0.2%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805305
05HumanNon-randomized trialEfficacy outcome
In treatment-naive women with osteoporosis, lumbar spine BMD increased by 8.4% from baseline during teriparatide treatment.
In plain wordsIn treatment-naive women with osteoporosis, spine bone density increased by 8.4% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in treatment-naive women
Study
n = 204
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Lumbar spine BMD increase
8.4%
treatment-naive
95% CI lower
7.4%
treatment-naive
95% CI upper
9.3%
treatment-naive
Source sentences
Summary
Lumbar spine BMD increased from baseline (p < 0.001) in the three groups (mean, 95% CI); treatment-naïve: 8.4% (7.4%, 9.3%); AR-pretreated: 7.1% (6.3%, 7.9%); inadequate AR-responders: 6.2% (5.6%, 6.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805301
06HumanNon-randomized trialEfficacy outcome
In treatment-naive women, total hip BMD increased by 1.8% from baseline during teriparatide treatment.
In plain wordsIn treatment-naive women, hip bone density increased by 1.8% from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD in treatment-naive women
Study
n = 204
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 1 yearAs given in this study (human).
Measurements
Total hip BMD change
1.8%
treatment-naive
95% CI lower
1.1%
treatment-naive
95% CI upper
2.5%
treatment-naive
Source sentences
Summary
Total hip BMD increased from baseline in the treatment-naïve (p < 0.001): 1.8% (1.1%, 2.5%) but did not change in the AR-pretreated: 0.4% (-0.2%, 1.1%) or inadequate AR-responders: -0.3% (-0.9%, 0.2%).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
Report a problemFND-1883805304

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In women receiving teriparatide, treatment-emergent adverse events were similar across prior-treatment groups.
In plain wordsIn women receiving teriparatide, adverse events were similar across prior-treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTreatment-emergent adverse events
Study
n = 865
Comparator
Other prior-treatment groups receiving teriparatide
Outcome group
Adverse events · Whole body
Source sentences
Summary
Treatment-emergent adverse events were similar in the three groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the secondary analysis described here was to evaluate the interim bone mineral density (BMD) response in these groups after one year of open-label teriparatide therapy.
Summary · context
Postmenopausal women with established osteoporosis who enrolled in a prospective, randomized, controlled trial received open-label teriparatide 20 µg/day for the first year.
Summary · context
With respect to their prior osteoporosis treatment history, they were retrospectively allocated to one of three groups: treatment-naïve (n = 204), prior treatment with an antiresorptive drug (AR-pretreated) (n = 240), or prior antiresorptive treatment with inadequate response (inadequate AR-responders) (n = 421).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1883805307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00191425

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Eli Lilly and Companyn = 810Aug 2002 to Nov 2005

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 16 Jul 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.